TERT and Alpha-thalassemia: Molecular markers, including 1p/19q co-deletion and mutations in TERT (encoding telomerase reverse transcriptase), P53, and ATRX (encoding alpha thalassemia/mental retardation syndrome X-linked chromatin remodeler), have been identified as crucial predictors of patient prognosis and treatment sensitivity [12–14].